

OKLAHOMA BOARD OF NURSING  
2915 North Classen Boulevard, Suite 524  
Oklahoma City, OK 73106  
(405) 962-1800

**CRNA Formulary Advisory Council**  
**AGENDA**  
**Monday, April 26, 2021**  
**3:30 p.m.**

This virtual Council meeting is being held consistent with the amendments to the Open Meeting Act, 25 O.S. 2011, § 301 *et seq*, signed into law by Governor Stitt on Wednesday, February 10, 2021. *See* SB1031, 2021 O.S.L. 1, § 2

**Website:** <http://nursing.ok.gov>

**Link to access meeting:** <https://obn.webex.com/obn/onstage/g.php?MTID=e96730966b4e4f9205c43f772ccd69720>

**Event Number:** 187 132 4472

**Password:** W3LCOME

Dial US: +1-415-655-0001 to join by audio

**Access code:** 187 132 4472

**Link to access meeting materials:** <http://nursing.ok.gov/agcrna21.pdf>. The Notice of this meeting was filed with the Secretary of State's Office on November 25, 2020, and was amended on April 14, 2021. Notice/final agenda was posted on April 19, 2021, at 5:00 PM, on the Cameron Building front entrance at 2915 N. Classen Blvd., Oklahoma City, at the Board office Suite 524, and on the Oklahoma Board of Nursing web site.

The CRNA Formulary Advisory Council members may discuss, vote to approve, vote to disapprove, vote to table, change the sequence of any agenda item, or vote to strike or not discuss any agenda item.

The following council members plan to participate remotely via the Cisco Webex Events electronic platform:

Victor Long, APRN-CRNA

Bruce Kennedy, APRN-CRNA

Brian Seacat, MD

Jeremy Almon, MD

Mark St. Cyr, DPh

Jan Palovik, MSA, RN, Oklahoma Board of Nursing (Ex-Officio Member)

Board staff representatives are:

Gina Stafford, BSN, RN

Jackye Ward, MS, RN

In the event electronic communications are lost or compromised during the meeting, the Oklahoma Board of Nursing will attempt to restore communications for a maximum of (2) two hours. If unable to restore communications the meeting will be adjourned.

## AGENDA

1. Call to order
  - 1.1. Declaration of a quorum (minimum of three members)
  - 1.2. Reminder that voting members include 2 anesthesiologists, 1 pharmacist, and 2 CRNAs  
59 O.S. §567.4b B.1.
2. Committee decision regarding approval of September 28, 2020, committee meeting minutes  
**(Attachment #1)**
3. Board Update: Verbal reports only, requiring no action or discussion by committee (verbal reports only)
  - 3.1 *Oklahoma Nursing Practice Act* Jackye Ward
  - 3.2 *Proposed Rules* Jackye Ward
  - 3.3 Optimal Regulatory Board System (ORBS) Licensing Data Base Jackye Ward
  - 3.4 American Association of Nurse Anesthetists: Ketamine Infusion Therapy for Psychiatric Disorder and Chronic Pain Management Practice Considerations Gina Stafford
  - 3.5 CRNA Formulary Advisory Council membership Gina Stafford
4. Committee review and recommendations of the DRAFT *CRNA Inclusionary Formulary*  
**(Attachment #2)**
5. Committee election of Chairperson and Vice Chairperson for CY 2022
6. Committee member determination for date of next meeting
  - 6.1 Date and time
7. Adjournment

# Attachment #1

OKLAHOMA BOARD OF NURSING  
2915 N. Classen Boulevard, Suite 524  
Oklahoma City, Oklahoma 73106

## **Virtual CRNA Formulary Advisory Council Minutes-September 28, 2020**

This virtual Council meeting is being held consistent with the amendments to the Open Meeting Act, 25 O.S. 2011, § 301 *et seq.*, signed into law by Governor Stitt on Wednesday, March 18, 2020. *See* SB661, 2020 O.S.L. 3, § 3

**Website:** [www.nursing.ok.gov](http://www.nursing.ok.gov)

**Link to access meeting:**

<https://obn.webex.com/obn/onstage/g.php?MTID=e5d5a4a0694f1984ac4392f3fb597d856>

**Event Number:** 146 864 1949

**Password:** jqWNUpr565

Dial US: +1-415-655-0001 to join by audio

**Access code:** 146 864 1949

**Link to access meeting materials:** <http://nursing.ok.gov/agcrna20.pdf>. The Notice of this meeting was filed with the Secretary of State's Office on November 27, 2019, and was amended on July 22, 2020, and September 15, 2020. Notice/final agenda was posted on September 17, 2020, at 1:00 PM, on the Cameron Building front entrance at 2915 N. Classen Blvd., Oklahoma City, at the Board office Suite 524, and on the Oklahoma Board of Nursing web site.

The CRNA Formulary Advisory Council members may discuss, vote to approve, vote to disapprove, vote to table, change the sequence of any agenda item, or vote to strike or not discuss any agenda item.

**Council members participating remotely via the Cisco Webex Events electronic platform:**

Bruce Kennedy, APRN-CRNA

Brian Seacat, MD

Jeremy Almon, MD

Mark St. Cyr, DPh

**Board member representative participating remotely via the Cisco Webex Events electronic platform:**

Liz Massey, DNP, RN, Oklahoma Board of Nursing President (Ex-Officio Member)

**Council members absent:**

Victor Long, APRN-CRNA

**Board member representative absent:**

Jan Palovik, MSA, APRN-CRNA, Oklahoma Board of Nursing Vice-President

# Attachment #1

## **Board staff representatives participating remotely via the Cisco Webex Events electronic platform:**

Gina Stafford, BSN, RN

Jackye Ward, MS, RN

It was announced that in the event electronic communications are lost or compromised during the meeting, the Oklahoma Board of Nursing will attempt to restore communications for a maximum of (2) two hours. If unable to restore communications the meeting will be adjourned.

**1.0 Call to order:** The meeting was called to order at 3:33PM by Bruce Kennedy, Chairperson.

**1.1 Declaration of a quorum:** A quorum was declared present.

**1.2 Reminder:** Voting members include 2 anesthesiologists, 1 pharmacists, and 2 CRNAs. [59 O.S. § 567.4b.B.1.]

**2.0 Council decision regarding approval of the April 22, 2019, meeting minutes:** The minutes were reviewed. A motion was made (M. St Cyr) and seconded to approve the minutes of April 22, 2019.

### **Voting:**

Yes:	(2)	B. Kennedy, M. St Cyr
No:	(0)	
Absent:	(1)	V. Long
Abstain	(2)	B. Seacat, J. Almon

### **Motion Carried.**

**3.0 Board of Nursing update (verbal reports requiring no action by Council):**

**3.1 Changes to the *Oklahoma Nursing Practice Act*:** J. Ward summarized changes to the *Oklahoma Nursing Practice Act*.

**3.2 Changes to the *Oklahoma Board of Nursing Rules*:** J. Ward summarized changes to the *Rules*.

**3.3 Optimal Regulatory Board System (ORBS):** J. Ward provided an overview of the new nurse licensing platform which will be implemented in October 13, 2020.

**3.4 Governor Kevin Stitt's request for exemption from the federal regulation requiring the CRNA to be supervised by a physician-G.** Stafford provide an overview of the governor's CRNA "op-out" provision with the Centers of Medicare and Medicaid Services (CMS).

# Attachment #1

- 3.5 Executive Orders related to COVID-19:** J. Ward summarized how the Board has responded to Executive Orders related to the declared health emergency in response to the national spread of COVID-19. The agency's Pandemic Emergency Rules, temporary licensing of out-of-state licensees and those granted temporary licenses through continuing qualification waivers, as well as employment of students and non-licensed graduates of Board-approved nursing education programs were reviewed.
- 3.6 CRNA Formulary Advisory Council membership:** G. Stafford reported the term for Dr. Thomas Tinker expired 7/31/2020. The Oklahoma Society of Anesthesiology has appointed Dr. Jeremy Almon to replace Dr. Thomas Tinker as representative to the Council. Also, the Oklahoma Society of Anesthesiology appointed Dr. Brian Seacat to replace Dr. Lad Yates in February, 2020, as representative to the CRNA Formulary Council.

**4.0 Council review and recommendations on revisions to the DRAFT CRNA Inclusionary Formulary:** Council members reviewed the DRAFT *CRNA Inclusionary Formulary*, #P-50A with proposed revisions. A list of new and updated monographs was provided to committee members. The proposed revisions include the addition of language to define a CRNA, the addition of the statute regarding the Formulary Advisory Council, the addition of three new drugs, and the removal of one discontinued drug. After discussion, it was moved (B. Kennedy) and seconded to approve the following revisions to the *CRNA Inclusionary Formulary*, #P-50A and recommend the DRAFT to the Board for approval:

- Additional language “CRNA is an Advanced Practice Registered Nurse who administers anesthesia in collaboration with a medical doctor, an osteopathic physician, a podiatric physician or a dentist licensed in this state and under conditions in which timely onsite consultation by such doctor, osteopath, podiatric physician or dentist is available.”
- Add statute 59 O.S. § 567.4b to the first paragraph
- Add three drugs:
  - Direct Thrombin Inhibitors-Bivalirudin 20:12.04.12
  - Remimazolam 28:24.08
  - Antiemetics, Miscellaneous-Amisulpride 56:22.92
- Remove one drug:
  - Ranitidine 56:28.12
- Update the reference for *AHFS Drug Information* to the current edition (2020)

**Voting:**

Yes: (4) J. Almon, B. Kennedy, B. Seacat, M. St Cyr  
No: (0)  
Absent: (1) V. Long

**Motion Carried.**

# Attachment #1

**5.0 Council election of Chairperson and Vice Chairperson for 2020:** It was moved (M. St Cyr) and seconded to appoint Bruce Kennedy as Chairperson and it was moved (B. Seacat) and seconded to appoint Dr. Jeremy Almon as Vice Chairperson for the next CRNA Formulary Advisory Council Meeting.

**Voting:**

Yes: (4) J. Almon, B. Kennedy, B. Seacat, M. St Cyr  
No: (0)  
Absent: (1) V. Long

**Motion Carried.**

**6.0 Council member determination for date of the next meeting:** The members discussed possible dates and times for the next meeting.

**6.1** Selected date and time for the next meeting will be Monday, April 26, 2021 at 3:30 PM.

**Voting:**

Yes: (4) J. Almon, B. Kennedy, B. Seacat, M. St Cyr  
No: (0)  
Absent: (1) V. Long

**Motion Carried.**

**7.0 Adjournment:** There being no further business, the meeting was adjourned at 4:19 PM.

## Attachment #2 (A-C)

OKLAHOMA BOARD OF NURSING  
2915 N. Classen Boulevard, Suite 524  
Oklahoma City, OK 73106  
(405) 962-1800  
[www.ok.gov/nursing](http://www.ok.gov/nursing)

### MEMORANDUM

TO: CRNA Inclusionary Formulary Advisory Council

FROM: Gina Stafford, RN  
Associate Director for Nursing Practice

DATE: April 14, 2021

RE: *CRNA Inclusionary Formulary*, #P-50A

---

Attached are draft revisions to the *CRNA Inclusionary Formulary*, # P-50A for your review. As a point of information, the Formulary Advisory Council is a statutory committee responsible for the development and submission to the Board recommendations for an inclusionary formulary which lists drugs or categories of drugs that shall be ordered or administered by Certified Registered Nurse Anesthetists. “The Board shall either accept or reject the recommendations made by the Council. No amendments to the recommended inclusionary formulary may be made by the Board without the approval of the Formulary Advisory Council.” [Oklahoma Nurse Practice Act, specifically 59 O.S. §567.4b A.3]

**Revisions/Rationale:** Changes include additional language to define “collaboration”, changing the statute listed under Regulatory Authority and updating the reference. No drugs were added or removed at this time.

The proposed revisions are noted in the DRAFT policy attached. Revisions are indicated using strikethrough for deletions and double underlining for additions. I have highlighted the changes for easy identification.

Information attached for your review includes:

- DRAFT *CRNA Inclusionary Formulary*, #P-50A [**Attachment #2**]
- Oklahoma Nurse Practice Act, specifically 59 O.S. §567.3a.10.h. [**Attachment A**]
- Oklahoma Nurse Practice Act, specifically 59 O.S. §567.4b [**Attachment B**]
- *AHFS Classification Drug Assignments 2020-2021* (The list includes new drugs since our last meeting.) [**Attachment C**]

**Staff and Others Involved:** J. Ward and G. Stafford

**Legal Implications:** There are no known legal implications.

## Attachment #2 (A-C)

**Fiscal Impact:** There is no fiscal impact anticipated with the proposed revisions.

**Recommendations/Requested Action:** The DRAFT policy is presented for review and decision with a recommendation to move forward for Board approval.



OKLAHOMA BOARD OF NURSING  
2915 North Classen Boulevard, Suite 524  
Oklahoma City, OK 73106  
405-962-1800

**CRNA Inclusionary Formulary**

**To be granted authority to select, order, obtain and administer drugs**, Certified Registered Nurse Anesthetists (CRNAs) must hold a current Registered Nurse license, be recognized as a CRNA in Oklahoma and meet the continuing education requirements noted in the *Rules of the Oklahoma Board of Nursing*, specifically 485:10-18-2. Pursuant to 59 O.S. § 567.3a.10 [*Oklahoma Nursing Practice Act*], a CRNA is an Advanced Practice Registered Nurse who administers anesthesia in collaboration with a medical doctor, an osteopathic physician, a podiatric physician or a dentist licensed in this state and under conditions in which timely onsite consultation by such doctor, osteopath, podiatric physician or dentist is available. The Formulary Advisory Council has been established to develop and submit to the Board recommendations for an inclusionary formulary pursuant to 59 O.S. § 567.4b. [*Oklahoma Nursing Practice Act*].

Pursuant to 59 O.S. § 567.3a.10.h [*Oklahoma Nursing Practice Act*], “collaboration” means an agreement between a medical doctor, osteopathic physician, podiatric physician or dentist performing the procedure or directly involved with the procedure and the Certified Registered Nurse Anesthetist working jointly toward a common goal providing services for the same patient.

The following Board-approved *CRNA Inclusionary Formulary* lists drugs that may be ordered, selected, obtained or administered during the **perioperative** and **periparturient** periods by CRNAs who have been granted authority by the Board to select, order, obtain, and administer drugs.

---

**4:00 Antihistamine Drugs**

4:04 First Generation Antihistamines

Diphenhydramine Hydrochloride

Promethazine Hydrochloride (see also 28:24.92 and 28:16.08.24)

**12:00 Autonomic Drugs**

12:04 Parasympathomimetic (Cholinergic) Agents

Neostigmine Bromide

Physostigmine Salicylate

Pyridostigmine Bromide

12:08 Anticholinergic Agents

12:08.08 Antimuscarinics/antispasmodics

Atropine

Glycopyrrolate

Ipratropium Bromide

Scopolamine

12:12 Sympathomimetic (Adrenergic) Agents

12:12.04  $\alpha$ -Adrenergic Agents

Board Approved: 1/20/98

OBN Policy/Guideline - #P-50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06

Page 1 of 10

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16; 7/25/17; 5/22/18; 5/21/19; 11/10/20

P: /Administration/Executive/Policies/Practice/P-50A CRNA Inclusionary Formulary

Midodrine  
Phenylephrine

12:12.08  $\beta$ -Adrenergic Agonists

12:12.08.04 Non-selective  $\beta$ -Adrenergic Agonists

Isoproterenol

12:12.08.08 Selective  $\beta_1$ -Adrenergic Agonists

Dobutamine

Dopamine

12:12.08.12 Selective  $\beta_2$ -Adrenergic Agonists

Albuterol/Levalbuterol

Formoterol

Indacaterol

Metaproterenol

Salmeterol

Terbutaline Sulfate

12:12.12  $\alpha$ - and  $\beta$ -Adrenergic Agonists

Ephedrine

Epinephrine

Norepinephrine

Pseudoephedrine

12:16 Sympatholytic (Adrenergic Blocking) Agents

12:16.04  $\alpha$ -Adrenergic Blocking Agents

12:16.04.04 Non-selective  $\alpha$ -Adrenergic Blocking Agents

Phentolamine

12:20 Skeletal Muscle Relaxants (all intravenous future new drugs approved)

12:20.04 Centrally Acting Skeletal Muscle Relaxants

Carisoprodol

Cyclobenzaprine

Metaxalone

Methocarbamol

Tizanidine

12:20.08 Direct-acting Skeletal Muscle Relaxants

Dantrolene Sodium

12:20.12 GABA-derivative Skeletal Muscle Relaxants

Baclofen

12:20.20 Neuromuscular Blocking Agents

Atracurium Besylate

Cisatracurium

Pancuronium Bromide

Rocuronium Bromide

Succinylcholine Chloride

Vecuronium Bromide

**16:00 Blood Derivatives**

Board Approved: 1/20/98

OBN Policy/Guideline - #P-50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06

Page 2 of 10

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16; 7/25/17; 5/22/18; 5/21/19; 11/10/20

P- /Administration/Executive/Policies/Practice/P-50A CRNA Inclusionary Formulary

Albumin Human  
Plasma Protein Fraction

**Blood and Blood Components (not in AHFS)**

**20:00 Blood Formation, Coagulation, and Thrombosis**

- 20:12 Antithrombotic Agents
  - 20:12.04 Anticoagulants
    - 20:12.04.12 Direct Thrombin Inhibitors
      - Bivalirudin
    - 20:12.04.16 Heparins
      - Enoxaparin
      - Heparin
  - 20:28 Antihemorrhagic Agents
    - 20:28.08 Antiheparin Agents
      - Protamine Sulfate
    - 20:28.16 Hemostatics
      - Aminocaproic Acid
      - Tranexamic Acid (TXA) (not in AHFS)
    - 20:28.92 Antihemorrhagic Agents, Misc.
      - Idarucizumab
      - Andexanet Alfa

**24:00 Cardiovascular Drugs**

- 24:04 Cardiac Drugs
  - 24:04.04 Antiarrhythmic Agents
    - 24:04.04.04 Class Ia Antiarrhythmics
      - Disopyramide
      - Procainamide
      - Quinidine
    - 24:04.04.08 Class Ib Antiarrhythmics
      - Lidocaine
    - 24:04.04.20 Class III Antiarrhythmics
      - Amiodarone
    - 24:04.04.24 Class IV Antiarrhythmics
      - Adenosine
    - 24:04.08 Cardiotonic Agents
      - Digoxin
  - 24:08 Hypotensive Agents
    - 24:08.16 Central  $\alpha$ -Agonists
      - Clonidine
      - Methyldopa
    - 24:08.20 Direct Vasodilators
      - Hydralazine
      - Sodium Nitroprusside

- 24:12 Vasodilating Agents
  - 24:12.08 Nitrates and Nitrites
    - Nitroglycerine
- 24:24 β-Adrenergic Blocking Agents
  - Atenolol
  - Esmolol Hydrochloride
  - Labetalol
  - Metoprolol
  - Nadolol
  - Propranolol
- 24:28 Calcium-Channel Blocking Agents
  - 24:28.08 Dihydropyridines
    - Nicardipine
    - Nifedipine
  - 24:28.92 Calcium-Channel Blocking Agents, Miscellaneous
    - Verapamil
- 24:32 Renin-Angiotensin-Aldosterone System Inhibitors
  - 24:32.04 Angiotensin-Converting Enzyme Inhibitors
    - Captopril
    - Enalaprilat/Enalapril

**28:00 Central Nervous System Agents**

- 28:04 General Anesthetics (all in this class approved including future new drugs)
  - 28:04.04 Barbiturates
    - Methohexital
  - 28:04.16 Inhalation Anesthetics (not in AHFS)
  - 28:04.92 General Anesthetics, Miscellaneous
    - Etomidate
    - Ketamine (not in AHFS)
    - Fospropofol
    - Propofol
- 28:08 Analgesics and Antipyretics
  - 28:08.04 Nonsteroidal Antiinflammatory Agents
    - 28:08.04.08 Cyclooxygenase-2 (COX-2) Inhibitors
      - Celecoxib
    - 28:08.04.24 Salicylates
      - Aspirin
    - 28:08.04.92 Other Nonsteroidal Anti-inflammatory Agents
      - Ibuprofen (PO or IV)
      - Indomethacin
      - Ketorolac
      - Meloxicam
  - 28:08.08 Opiate Agonists (all in this class approved including future new drugs)
    - Codeine
    - Fentanyl

- Hydrocodone
- Hydromorphone
- Levorphanol
- Meperidine
- Morphine
- Remifentanyl
- Sufentanyl Citrate
- Tramadol
- 28:08.12 Opiate Partial Agonists (all in this class approved including future new drugs)
  - Buprenorphine
  - Butorphanol
  - Nalbuphine
- 28:08.92 Analgesics and Antipyretic, Miscellaneous
  - Acetaminophen (PO or IV)
  - Sodium Thiosalicylate
- 28:10 Opiate Antagonists (all in this class approved including future new drugs)
  - Nalmefene
  - Naloxone
  - Naltrexone
- 28:12 Anticonvulsants
  - 28:12.04 Barbituates
    - Phenobarbital
  - 28:12.08 Benzodiazepines
    - Clonazepam (see also 28:24.08)
  - 28:12.12 Hydantoins
    - Ethotoin
    - Fosphenytoin
    - Phenytoin
  - 28:12.92 Anticonvulsants, Miscellaneous
    - Carbamazepine
    - Felbamate
    - Gabapentin
    - Lamotrigine
    - Magnesium Sulfate
    - Valproate/Divalproex
- 28:16 Psychotherapeutic Agents
  - 28:16.08 Antipsychotics
    - 28:16.08.04 Atypical Antipsychotics
    - 28:16.08.08 Butyrophenones
      - Haloperidol
    - 28:16.08.24 Phenothiazines
      - Perphenazine
      - Prochlorperazine
- 28:20 Anorexigenic Agents and Respiratory and CNS Stimulants
  - 28:20.32 Respiratory and CNS Stimulants

Caffeine/Caffeine and Sodium Benzoate  
Doxapram

- 28:24 Anxiolytics, Sedatives, and Hypnotics  
28:24.04 Barbiturates (all in this class approved including future new drugs)  
Phenobarbital  
28:24.08 Benzodiazepines (all in this class approved including future new drugs)  
Alprazolam  
Chlordiazepoxide  
Diazepam  
Lorazepam  
Midazolam  
Remimazolam  
Temazepam  
28:24.92 Anxiolytics, Sedatives, and Hypnotics, Miscellaneous  
Dexmedetomidine  
Hydroxyzine  
Promethazine  
28:36 Antiparkinsonian Agents  
28:36.08 Anticholinergic Agents  
Benztropine Mesylate  
28:92 Central Nervous System Agents, Miscellaneous  
Flumazenil

**36:00 Diagnostic Agents**

- 36:40 Kidney Function  
Indigo Carmine (Indigotindisulfonate)  
36:56 Myasthenia Gravis  
Edrophonium Chloride

**40:00 Electrolytic, Caloric, and Water Balance**

- 40:08 Alkalinizing Agents  
Citrates (i.e., potassium citrate and citric acid, sodium citrate and citric acid, tricitrates)  
Sodium Bicarbonate  
Sodium Lactate  
40:12 Replacement Preparations  
Calcium Salts  
Dextran 40  
Electrolyte Solutions  
Hetastarch  
Potassium Supplements  
Sodium Chloride  
40:20 Caloric Agents  
Dextrose

Invert Sugar  
40:24 Salt and Sugar Substitutes (not in AHFS)

40:28 Diuretics  
40:28.08 Loop Diuretics  
Bumetanide  
Furosemide  
40:28.12 Osmotic Diuretics  
Mannitol  
40:28.20 Thiazide Diuretics  
Chlorothiazide

**48:00 Respiratory Tract Agents** (all in this class approved including future new drugs)

48:08 Antitussives  
Benzonatate  
Codeine  
Dextromethorphan  
Hydrocodone  
48:16 Expectorants  
Guaifenesin  
Potassium Iodide (see also 68:36.08)  
48:24 Mucolytic Agents  
Acetylcysteine (see also 92:12)

**52:00 Eye, Ear, Nose, and Throat (EENT) Preparations**

52:16 Local Anesthetics  
Benzocaine  
Dyclonine  
Proparacaine  
Tetracaine  
52:32 Vasoconstrictors  
Epinephrine  
Naphazoline  
Oxymetazoline  
Phenylephrine  
Propylhexedrine  
Tetrahydrozine  
52:40 Antiglaucoma Agents  
52:40.12 Carbonic Anhydrase Inhibitors  
Acetazolamide

**56:00 Gastrointestinal Drugs**

56:04 Antacids and Adsorbents  
Aluminum Carbonate  
Aluminum Hydroxide  
Aluminum Phosphate  
Antacids

Board Approved: 1/20/98

OBN Policy/Guideline - #P-50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06

Page 7 of 10

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16; 7/25/17; 5/22/18; 5/21/19; 11/10/20

P-50A Administration/Executive/Policies/Practice/P-50A CRNA Inclusionary Formulary

- Calcium Carbonate
- Charcoal, Activated
- Dihydroxyaluminum Aminoacetate
- Dihydroxyaluminum Sodium Carbonate
- Magaldrate
- Magnesium Carbonate
- Magnesium Hydroxide
- Magnesium Oxide
- Magnesium Trisilicate
- Sodium Bicarbonate
- 56:22 Antiemetics
  - 56:22.08 Antihistamines
    - Dimenhydrinate
    - Meclizine
    - Prochlorperazine
    - Trimethobenzamide
  - 56:22.20 5-HT<sub>3</sub> Receptor Antagonists
    - Dolasetron
    - Granisetron
    - Ondansetron
  - 56:22.92 Antiemetics, Miscellaneous
    - Amisulpride
- 56:28 Antiulcer Agents and Acid Suppressants
  - 56:28.12 Histamine H<sub>2</sub>-Antagonists
    - Cimetidine
    - Famotidine
    - Nizatidine
  - 56:28.32 Protectants
    - Sucralfate
  - 56:28.36 Proton-pump Inhibitors
    - Dexlansoprazole
    - Esomeprazole
    - Lansoprazole
    - Omeprazole
    - Pantoprazole
    - Rabeprazole
- 56:32 Prokinetic Agents
  - Metoclopramide

**68:00 Hormones and Synthetic Substitutes**

- 68:04 Adrenals (all in this class approved including future new drugs)
  - Beclomethasone
  - Betamethasone
  - Cortisone Acetate
  - Dexamethasone
  - Fludrocortisone
  - Flunisolide
  - Hydrocortisone



- Methylprednisolone
- Prednisolone
- Prednisone
- Triamcinolone
- 68:20 Antidiabetic Agents
  - 68:20.08 Insulins
    - 68:20.08.04 Rapid-acting Insulins
      - Insulin Aspart
      - Insulin Glulisine
      - Insulin Lispro
    - 68:20.08.08 Short-acting Insulins
      - Insulin Human
      - Insulin Isophane (not in AHFS)
    - 68:20.08.16 Long-acting Insulins
      - Insulin Glargine
  - 68:20.20 Sulfonylureas
    - Chlorpropamide
    - Glimepiride
    - Glipizide
    - Glyburide
    - Tolazamide
    - Tolbutamide
- 68:22 Antihypoglycemic Agents
  - 68:22.12 Glycogenolytic Agents
    - Glucagon
- 68:28 Pituitary
  - Corticotropin
  - Desmopressin
  - Vasopressin
- 68:44 Renin-Angiotensin-Aldosterone System (RAAS)
  - Angiotensin II (not in AHFS)

**72:00 Local Anesthetics** (all in this class approved including future new drugs)

- Articaine
- Bupivacaine
- Chloroprocaine
- Lidocaine
- Mepivacaine
- Prilocaine
- Procaine (not in AHFS)
- Ropivacaine (not in AHFS)
- Tetracaine

**76:00 Oxytocics**

- Carboprost Tromethamine
- Dinoprostone
- Ergonovine/Methergonovine
- Oxytocin

Sodium Chloride 20% Injection  
Urea 40-50% Injection

**84:00 Skin and Mucous Membrane Agents**

84:04 Anti-infective

84:04.92 Local Anti-Infectives, Miscellaneous  
Chlorhexidine gluconate

84:08 Antipruritics and Local Anesthetics (all in this class approved including future new drugs)

Benzocaine

Dibucaine

Doxepin

Ethyl Chloride

Phenazopyridine

Pramoxine

**86:00 Smooth Muscle Relaxants**

86:16 Respiratory Smooth Muscle Relaxants

Aminophylline

Theophyllines

**92:00 Miscellaneous Therapeutic Agents**

92:12 Antidotes

Acetylcysteine

Methylene Blue

Sugammadex

**[NOTE: ACLS Algorithm medications are listed according to the classification system in the AHFS Drug Information resource.]**

**Regulatory Authority:**

59 O.S. §567.4b. C.

**Reference:**

American Hospital Formulary Service®. *AHFS Drug Information (2020/2021)*. Published by Authority of the Board of the American Society of Health-System Pharmacists®, Bethesda, MD.

Attachment # 2 A



**OKLAHOMA**  
State Courts Network

**Title 59. Professions and Occupations**

**Oklahoma Statutes Citationized**

**Title 59. Professions and Occupations**

**Chapter 12 - Nurses**

**Oklahoma Nursing Practice Act**

**Section 567.3a - Definitions**

Cite as: O.S. §. \_\_\_

As used in the Oklahoma Nursing Practice Act:

1. "Board" means the Oklahoma Board of Nursing;
2. "The practice of nursing" means the performance of services provided for purposes of nursing diagnosis and treatment of human responses to actual or potential health problems consistent with educational preparation. Knowledge and skill are the basis for assessment, analysis, planning, intervention, and evaluation used in the promotion and maintenance of health and nursing management of illness, injury, infirmity, restoration or optimal function, or death with dignity. Practice is based on understanding the human condition across the human lifespan and understanding the relationship of the individual within the environment. This practice includes execution of the medical regime including the administration of medications and treatments prescribed by any person authorized by state law to so prescribe;
3. "Registered nursing" means the practice of the full scope of nursing which includes, but is not limited to:
  - a. assessing the health status of individuals, families and groups,
  - b. analyzing assessment data to determine nursing care needs,
  - c. establishing goals to meet identified health care needs,
  - d. planning a strategy of care,
  - e. establishing priorities of nursing intervention to implement the strategy of care,
  - f. implementing the strategy of care,
  - g. delegating such tasks as may safely be performed by others, consistent with educational preparation and that do not conflict with the provisions of the Oklahoma Nursing Practice Act,
  - h. providing safe and effective nursing care rendered directly or indirectly,
  - i. evaluating responses to interventions,
  - j. teaching the principles and practice of nursing,
  - k. managing and supervising the practice of nursing,
  - l. collaborating with other health professionals in the management of health care,
  - m. performing additional nursing functions in accordance with knowledge and skills acquired beyond basic

A

nursing preparation, and

n. delegating those nursing tasks as defined in the rules of the Board that may be performed by an advanced unlicensed assistive person;

4. "Licensed practical nursing" means the practice of nursing under the supervision or direction of a registered nurse, licensed physician or dentist. This directed scope of nursing practice includes, but is not limited to:

a. contributing to the assessment of the health status of individuals and groups,

b. participating in the development and modification of the plan of care,

c. implementing the appropriate aspects of the plan of care,

d. delegating such tasks as may safely be performed by others, consistent with educational preparation and that do not conflict with the Oklahoma Nursing Practice Act,

e. providing safe and effective nursing care rendered directly or indirectly,

f. participating in the evaluation of responses to interventions,

g. teaching basic nursing skills and related principles,

h. performing additional nursing procedures in accordance with knowledge and skills acquired through education beyond nursing preparation, and

i. delegating those nursing tasks as defined in the rules of the Board that may be performed by an advanced unlicensed assistive person;

5. "Advanced Practice Registered Nurse" means a licensed Registered Nurse:

a. who has completed an advanced practice registered nursing education program in preparation for one of four recognized advanced practice registered nurse roles,

b. who has passed a national certification examination recognized by the Board that measures the advanced practice registered nurse role and specialty competencies and who maintains recertification in the role and specialty through a national certification program,

c. who has acquired advanced clinical knowledge and skills in preparation for providing both direct and indirect care to patients; however, the defining factor for all Advanced Practice Registered Nurses is that a significant component of the education and practice focuses on direct care of individuals,

d. whose practice builds on the competencies of Registered Nurses by demonstrating a greater depth and breadth of knowledge, a greater synthesis of data, and increased complexity of skills and interventions, and

e. who has obtained a license as an Advanced Practice Registered Nurse in one of the following roles: Certified Registered Nurse Anesthetist, Certified Nurse-Midwife, Clinical Nurse Specialist, or Certified Nurse Practitioner.

Only those persons who hold a license to practice advanced practice registered nursing in this state shall have the right to use the title "Advanced Practice Registered Nurse" and to use the abbreviation "APRN". Only those persons who have obtained a license in the following disciplines shall have the right to fulfill the roles and use the applicable titles: Certified Registered Nurse Anesthetist and the abbreviation "CRNA", Certified Nurse-Midwife and the abbreviation "CNM", Clinical Nurse Specialist and the abbreviation "CNS", and Certified Nurse Practitioner and the abbreviation "CNP".

It shall be unlawful for any person to assume the role or use the title Advanced Practice Registered Nurse or use the abbreviation "APRN" or use the respective specialty role titles and abbreviations or to use any other titles or abbreviations that would reasonably lead a person to believe the user is an Advanced Practice Registered Nurse, unless permitted by the Oklahoma Nursing Practice Act. Any individual doing so shall be guilty of a misdemeanor, which shall be punishable, upon conviction, by imprisonment in the county jail for not more than one (1) year or by a fine of not less than One Hundred Dollars (\$100.00) nor more than One Thousand Dollars (\$1,000.00), or by both such imprisonment and fine for each offense;

6. "Certified Nurse Practitioner" is an Advanced Practice Registered Nurse who performs in an expanded role in the delivery of health care:

- a. consistent with advanced educational preparation as a Certified Nurse Practitioner in an area of specialty,
- b. functions within the Certified Nurse Practitioner scope of practice for the selected area of specialization, and
- c. is in accord with the standards for Certified Nurse Practitioners as identified by the certifying body and approved by the Board.

A Certified Nurse Practitioner shall be eligible, in accordance with the scope of practice of the Certified Nurse Practitioner, to obtain recognition as authorized by the Board to prescribe, as defined by the rules promulgated by the Board pursuant to this section and subject to the medical direction of a supervising physician. This authorization shall not include dispensing drugs, but shall not preclude, subject to federal regulations, the receipt of, the signing for, or the dispensing of professional samples to patients.

The Certified Nurse Practitioner accepts responsibility, accountability, and obligation to practice in accordance with usual and customary advanced practice registered nursing standards and functions as defined by the scope of practice/role definition statements for the Certified Nurse Practitioner;

7. a. "Clinical Nurse Specialist" is an Advanced Practice Registered Nurse who holds:

- (1) a master's degree or higher in nursing with clinical specialization preparation to function in an expanded role,
- (2) specialty certification from a national certifying organization recognized by the Board,
- (3) an Advanced Practice Registered Nurse license from the Board, and
- (4) any nurse holding a specialty certification as a Clinical Nurse Specialist valid on January 1, 1994, granted by a national certifying organization recognized by the Board, shall be deemed to be a Clinical Nurse Specialist under the provisions of the Oklahoma Nursing Practice Act.

b. In the expanded role, the Clinical Nurse Specialist performs at an advanced practice level which shall include, but not be limited to:

- (1) practicing as an expert clinician in the provision of direct nursing care to a selected population of patients or clients in any setting, including private practice,
- (2) managing the care of patients or clients with complex nursing problems,
- (3) enhancing patient or client care by integrating the competencies of clinical practice, education, consultation, and research, and
- (4) referring patients or clients to other services.

A

c. A Clinical Nurse Specialist in accordance with the scope of practice of such Clinical Nurse Specialist shall be eligible to obtain recognition as authorized by the Board to prescribe, as defined by the rules promulgated by the Board pursuant to this section, and subject to the medical direction of a supervising physician. This authorization shall not include dispensing drugs, but shall not preclude, subject to federal regulations, the receipt of, the signing for, or the dispensing of professional samples to patients.

d. The Clinical Nurse Specialist accepts responsibility, accountability, and obligation to practice in accordance with usual and customary advanced practice nursing standards and functions as defined by the scope of practice/role definition statements for the Clinical Nurse Specialist;

8. "Nurse-Midwife" is a nurse who has received an Advanced Practice Registered Nurse license from the Oklahoma Board of Nursing who possesses evidence of certification according to the requirements of the American College of Nurse-Midwives.

A Certified Nurse-Midwife in accordance with the scope of practice of such Certified Nurse-Midwife shall be eligible to obtain recognition as authorized by the Board to prescribe, as defined by the rules promulgated by the Board pursuant to this section and subject to the medical direction of a supervising physician. This authorization shall not include the dispensing of drugs, but shall not preclude, subject to federal regulations, the receipt of, the signing for, or the dispensing of professional samples to patients.

The Certified Nurse-Midwife accepts responsibility, accountability, and obligation to practice in accordance with usual and customary advanced practice registered nursing standards and functions as defined by the scope of practice/role definition statements for the Certified Nurse-Midwife;

9. "Nurse-midwifery practice" means providing management of care of normal newborns and women, antepartally, intrapartally, postpartally and gynecologically, occurring within a health care system which provides for medical consultation, medical management or referral, and is in accord with the standards for nurse-midwifery practice as defined by the American College of Nurse-Midwives;

10. a. "Certified Registered Nurse Anesthetist" is an Advanced Practice Registered Nurse who:

(1) is certified by the National Board of Certification and Recertification for Nurse Anesthetists as a Certified Registered Nurse Anesthetist within one (1) year following completion of an approved certified registered nurse anesthetist education program, and continues to maintain such recertification by the National Board of Certification and Recertification for Nurse Anesthetists, and

(2) administers anesthesia in collaboration with a medical doctor, an osteopathic physician, a podiatric physician or a dentist licensed in this state and under conditions in which timely onsite consultation by such doctor, osteopath, podiatric physician or dentist is available.

b. A Certified Registered Nurse Anesthetist, in collaboration with a medical doctor, osteopathic physician, podiatric physician or dentist licensed in this state, and under conditions in which timely, on-site consultation by such medical doctor, osteopathic physician, podiatric physician or dentist is available, shall be authorized, pursuant to rules adopted by the Oklahoma Board of Nursing, to order, select, obtain and administer legend drugs, Schedules II through V controlled substances, devices, and medical gases only when engaged in the preanesthetic preparation and evaluation; anesthesia induction, maintenance and emergence; and postanesthesia care. A Certified Registered Nurse Anesthetist may order, select, obtain and administer drugs only during the perioperative or peribstretical period.

c. A Certified Registered Nurse Anesthetist who applies for authorization to order, select, obtain and administer

A

drugs shall:

- (1) be currently recognized as a Certified Registered Nurse Anesthetist in this state,
- (2) provide evidence of completion, within the two-year period immediately preceding the date of application, of a minimum of fifteen (15) units of continuing education in advanced pharmacology related to the administration of anesthesia as recognized by the National Board of Certification and Recertification for Nurse Anesthetists, and
- (3) complete and submit a notarized application, on a form prescribed by the Board, accompanied by the application fee established pursuant to this section.

d. The authority to order, select, obtain and administer drugs shall be terminated if a Certified Registered Nurse Anesthetist has:

- (1) ordered, selected, obtained or administered drugs outside of the Certified Registered Nurse Anesthetist scope of practice or ordered, selected, obtained or administered drugs for other than therapeutic purposes, or
- (2) violated any provision of state laws or rules or federal laws or regulations pertaining to the practice of nursing or the authority to order, select, obtain and administer drugs.

e. The Oklahoma Board of Nursing shall notify the Board of Pharmacy after termination of or a change in the authority to order, select, obtain and administer drugs for a Certified Registered Nurse Anesthetist.

f. The Board shall provide by rule for biennial application renewal and reauthorization of authority to order, select, obtain and administer drugs for Certified Registered Nurse Anesthetists. At the time of application renewal, a Certified Registered Nurse Anesthetist shall submit documentation of a minimum of eight (8) units of continuing education, completed during the previous two (2) years, in advanced pharmacology relating to the administration of anesthesia, as recognized by the Council on Recertification of Nurse Anesthetists or the Council on Certification of Nurse Anesthetists.

g. This paragraph shall not prohibit the administration of local or topical anesthetics as now permitted by law. Provided further, nothing in this paragraph shall limit the authority of the Board of Dentistry to establish the qualifications for dentists who direct the administration of anesthesia.

h. As used in this paragraph, "collaboration" means an agreement between a medical doctor, osteopathic physician, podiatric physician or dentist performing the procedure or directly involved with the procedure and the Certified Registered Nurse Anesthetist working jointly toward a common goal providing services for the same patient. This collaboration involves the joint formulation, discussion and agreement of the anesthesia plan by both parties, and the collaborating medical doctor, osteopathic physician, podiatric physician or dentist performing the procedure or directly involved with the procedure and that collaborating physician shall remain available for timely onsite consultation during the delivery of anesthesia for diagnosis, consultation, and treatment of medical conditions;

11. "Supervising physician" means an individual holding a current license to practice as a physician from the State Board of Medical Licensure and Supervision or the State Board of Osteopathic Examiners, who supervises a Certified Nurse Practitioner, a Clinical Nurse Specialist, or a Certified Nurse-Midwife, and who is not in training as an intern, resident, or fellow. To be eligible to supervise such Advanced Practice Registered Nurse, such physician shall remain in compliance with the rules promulgated by the State Board of Medical Licensure and Supervision or the State Board of Osteopathic Examiners;

A

12. "Supervision of an Advanced Practice Registered Nurse with prescriptive authority" means overseeing and accepting responsibility for the ordering and transmission by a Certified Nurse Practitioner, a Clinical Nurse Specialist, or a Certified Nurse-Midwife of written, telephonic, electronic or oral prescriptions for drugs and other medical supplies, subject to a defined formulary; and

13. "Advanced Unlicensed Assistant" means any person who has successfully completed a certified training program approved by the Board that trains the Advanced Unlicensed Assistant to perform specified technical skills identified by the Board in acute care settings under the direction and supervision of the Registered Nurse or Licensed Practical Nurse.

#### Historical Data

Laws 1991, HB 1760, c. 104, § 2, eff. September 1, 1991; Amended by Laws 1994, HB 2128, c. 97, § 2, emerg. eff. July 1, 1994; Amended by Laws 1996, SB 537, c. 136, § 1 (repealed by Laws 1996, SB 1320, c. 288, § 9, eff. November 1, 1996); Amended by Laws 1996, SB 587, c. 186, § 4, eff. November 1, 1996; Amended by Laws 1996, HB 2250, c. 318, § 13, emerg. eff. July 1, 1996; Amended by Laws 1996, SB 1320, c. 288, § 2, eff. November 1, 1996 ([superseded document available](#)); Amended by Laws 1997, SB 275, c. 250, § 6, eff. November 1, 1997 ([superseded document available](#)); Amended by Laws 1998, HB 2685, c. 71, § 1, eff. November 1, 1998 ([superseded document available](#)); Amended by Laws 2001, HB 1214, c. 33, § 46, emerg. eff. July 1, 2001 ([superseded document available](#)); Amended by Laws 2001, SB 377, c. 254, § 2, eff. November 1, 2001 ([superseded document available](#)); Amended by Laws 2011, HB 1275, c. 101, § 1, eff. November 1, 2011 ([superseded document available](#)); Amended by Laws 2017, HB 1886, c. 281, § 1, eff. November 1, 2017 ([superseded document available](#)); Amended by Laws 2020, SB 801, c. 11, § 1, emerg. eff. May 7, 2020 ([superseded document available](#)).

#### Citationizer® Summary of Documents Citing This Document

Cite Name	Level
<b>Oklahoma Attorney General's Opinions</b>	
<i>Cite</i>	<i>Name</i> <span style="float: right;"><i>Level</i></span>
<a href="#">2008 OK AG 26</a>	<a href="#">Question Submitted by: The Honorable Mike Shelton, State Representative, District 97, James Gormley, M.D., President, Okla. State Bd. of Medical Licensure and Supervision, Kim Glazier, R.N., M.Ed., Executive Director, Okla. Bd. of Nursing</a> <span style="float: right;">Discussed at Length</span>
<a href="#">2012 OK AG 21</a>	<a href="#">Question Submitted by: Executive Director, Kim Glazier, RN, M.Ed., Oklahoma Board of Nursing</a> <span style="float: right;">Discussed at Length</span>
<a href="#">1998 OK AG 24</a>	<a href="#">Question Submitted by: Lyle Kelsey, Executive Director, Oklahoma State Board of Medical Licensure and Supervision</a> <span style="float: right;">Discussed at Length</span>
<b>Oklahoma Supreme Court Cases</b>	
<i>Cite</i>	<i>Name</i> <span style="float: right;"><i>Level</i></span>
<a href="#">2006 OK 39, 143 P.3d 203</a>	<a href="#">GAINES v. COMANCHE COUNTY MEDICAL HOSPITAL</a> <span style="float: right;">Cited</span>
<b>Oklahoma Session Laws - 2001</b>	
<i>Cite</i>	<i>Name</i> <span style="float: right;"><i>Level</i></span>
<a href="#">2001 O.S.L. 33, 2001 O.S.L. 33</a>	<a href="#">Vocational technical education; changing the name of area vocational technical school districts to technology center school districts; changing statutory cites. Effective date. Emergency.</a> <span style="float: right;">Discussed</span>



A

**Cite Name** **Level**

**Title 59. Professions and Occupations**

<i>Cite</i>	<i>Name</i>	<i>Level</i>
<u>59 O.S. 353.1</u>	<u>Definitions</u>	<i>Cited</i>
<u>59 O.S. 567.4a</u>	<u>Rules Regarding Prescriptive Authority Recognition</u>	<i>Discussed</i>
<u>59 O.S. 567.4b</u>	<u>Establishment of Formulary Advisory Council</u>	<i>Cited</i>

**Title 63. Public Health and Safety**

<i>Cite</i>	<i>Name</i>	<i>Level</i>
<u>63 O.S. 2-101</u>	<u>Definitions</u>	<i>Cited</i>

**Citationizer: Table of Authority**

---

**Cite Name** **Level**

**Title 59. Professions and Occupations**

<i>Cite</i>	<i>Name</i>	<i>Level</i>
<u>59 O.S. 567.3a</u>	<u>Terms Defined</u>	<i>Cited</i>
<u>59 O.S. 567.3a</u>	<u>Definitions</u>	<i>Cited</i>

Attachment # 2 B



OKLAHOMA  
State Courts Network

**Title 59. Professions and Occupations**

**Oklahoma Statutes Citationized**

**Title 59. Professions and Occupations**

**Chapter 12 - Nurses**

**Oklahoma Nursing Practice Act**

**Section 567.4b - Establishment of Formulary Advisory Council**

Cite as: O.S. §, \_\_\_

A. 1. The rules regarding authorization for a certified registered nurse anesthetist to order, select, obtain and administer drugs, promulgated by the Oklahoma Board of Nursing pursuant to paragraph 10 of Section 567.3a of Title 59 of the Oklahoma Statutes, shall provide for establishment of a Formulary Advisory Council to develop and submit to the Board recommendations for an inclusionary formulary that lists drugs or categories of drugs that may be ordered, selected, obtained or administered by certified registered nurse anesthetists authorized by the Board to order, select, obtain and administer drugs.

2. Such Formulary Advisory Council shall also develop and submit to the Board recommendations for practice-specific standards for ordering, selecting, obtaining and administering drugs for a certified registered nurse anesthetist authorized by the Board to order, select, obtain and administer drugs pursuant to the provisions of the Oklahoma Nursing Practice Act.

3. The Board shall either accept or reject the recommendations of the Council. No amendments to the recommended inclusionary formulary may be made by the Board without the approval of the Formulary Advisory Council.

B. 1. The Formulary Advisory Council shall be composed of five (5) members as follows:

- a. two certified registered nurse anesthetists, appointed by the Oklahoma Association of Nurse Anesthetists located in this state,
- b. two anesthesiologists, appointed by the Oklahoma Society of Anesthesiologists located in this state, and
- c. a hospital-based pharmacist appointed by the Oklahoma Pharmaceutical Association located in this state.

2. All professional members of the Formulary Advisory Council shall be in active clinical practice at least fifty percent (50%) of the time within their defined area of specialty.

3. a. Members of the Formulary Advisory Council shall serve at the pleasure of their appointing authority for a term of three (3) years. The terms of the members shall be staggered. Members of the Council may serve beyond the expiration of their term of office until a successor is appointed by the original appointing authority.

b. Members of the Council shall elect a chair and a vice-chair from among the membership of the Council. Three members shall constitute a quorum for the transaction of business.



Attachment #2 C

## DrugAssignments

Drug Name	Active Ingredients	Company	Indication	Approval Date	AHFS Class	NDA Type	Appl No
Qelbree®	viloxazine	Supernus Pharms	ADHD	2021/04/02	28:92 - Central Nervous System Agents, Miscellaneous	1S/O	211964
Abecma®	idecabtagene vicleucel	Bristol Myers Squibb	multiple myeloma	2021/03/26	26:12 - Gene Therapy	BLA	125736
Zegalogue®	dasiglucagon	Zealand Pharma	severe hypoglycemia	2021/03/22	68:22.12 - Glycogenolytic Agents	1S/O	214231
Ponvory®	ponesimod	Janssen	multiple sclerosis	2021/03/18	92:20 - Immunomodulatory Agents	1S/O	213498
Fotivda®	tivozanib	Aveo Pharmaceuticals Inc	Renal Cell Carcinoma	2021/03/10	10:00 - Antineoplastic Agents	1S/O	212904
Azstarys®	serdexmethylphenidate; dexmethylphenidate	Commcave Therapeutics SA	ADHD	2021/03/02	28:20.32 - Respiratory and CNS Stimulants	1S/O	212994
COVID-19 Vaccine (Janssen)	SARS-CoV-2 (COVID-19) vaccine, Adenovirus Vector	Janssen Biotech, Inc.	COVID-19	2021/02/27	80:12 - Vaccines	EUA	EUA
Nulibry®	fosdenopterin	Origin Biosciences Inc	molybdenum cofactor deficiency (MoCD) type a	2021/02/26	92:92 - Other Miscellaneous Therapeutic Agents	1P/O	214018
Pepaxto®	melphalan flufenamide	Oncopeptides AB	relapsed or refractory multiple myeloma	2021/02/26	10:00 - Antineoplastic Agents	1P/O	214383
Amondys 45®	casimersen	Sarepta Therapeutics, Inc.	Duchenne Muscular Dystrophy	2021/02/25	92:18 - Antisense Oligonucleotides	1P/O	213026
Cosela®	trilaciclib	G1 Therapeutics, Inc.	chemotherapy-induced myelosuppression	2021/02/12	92:56 - Protective Agents	1P/O	214200
Evkeeza®	evinacumab-dgnb	Regeneron Pharmaceuticals	homozygous familial hypercholesterolemia	2021/02/11	24:06.92 - Antilipemic Agents, Miscellaneous	BLA	761181
bamlanivimab; etesevimab	bamlanivimab; etesevimab	Eli Lilly and Company	COVID-19	2021/02/09	8:18.24 - Monoclonal Antibodies	EUA	EUA
Ukoniq®	umbralisib	TG Therapeutics, Inc.	marginal zone lymphoma	2021/02/05	10:00 - Antineoplastic Agents	1P/O	213176
Breyanzi®	lisocabtagene maraleucel	Juno Therapeutics, Inc	non-Hodgkin lymphoma	2021/02/05	26:12 - Gene Therapy; 10:00 - Antineoplastic Agents	BLA	145712
Tepmetko®	tepotinib	Emd Serono, Inc.	non-small cell lung cancer	2021/02/03	10:00 - Antineoplastic Agents	1P/O	214096
Lupkynis®	voclosporin	Aurinia Pharmaceuticals, Inc.	lupus nephritis	2021/01/22	92:44 - Immunosuppressive Agents	1P/O	213716
Cabenuva®	cabotegravir and rilpivirine	Viiv Healthcare	HIV	2021/01/21	8:18.08.12 - HIV Integrase Inhibitor	1P/O	212888

C

Drug Name	Active Ingredients	Company	Indication	Approval Date	AHFS Class	NDA Type	Appl No
Vocabria®	cabotegravir	Viiv Healthcare	HIV	2021/01/21	8:18.08.12 - HIV Integrase Inhibitors	1P/O	212887
Verquvo®	vericiguat	Merck Sharp Dohme	heart failure	2021/01/19	24:12.92 - Vasodilating Agents, Miscellaneous	1P/O	214377
Gemtesa®	vibegron	Urovant Sciences	overactive bladder	2020/12/23	86:12.08.12 - Selective beta-3 Adrenergic Agonists	1S/O	213006
Ebanga®	ansuvimab-zykl	Ridgeback Biotherapeutics	zaire ebolavirus infection	2020/12/21	8:18.24 - Monoclonal Antibodies	Orphan	761172
Orgovyx®	relugolix	Myovant Sciences	prostate cancer	2020/12/18	68:18.04 - Antigonadotropins	1P/O	214621
COVID-19 Vaccine (Moderna)	SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein	Moderna	COVID-19	2020/12/18	80:12 - Vaccines	EUA	EUA
Margenza®	margetuximab-cmkb	MacroGenics	HER2 positive breast cancer	2020/12/16	10:00 - Antineoplastic Agents	BLA	761150
Klisyri®	tirbanibulin	Athenex	actinic keratosis	2020/12/14	84:92 - Skin and Mucous Membrane Agents, Miscellaneous	1S/O	213189
COVID-19 Vaccine (Pfizer-BioNTech)	SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein	Pfizer-BioNTech	COVID-19	2020/12/11	80:12 - Vaccines	EUA	EUA
Orladeyo®	berotralstat	Biocryst	hereditary angioedema	2020/12/03	92:32 - Complement Inhibitors	1S/O	214094
Thyquidity®	levothyroxine sodium	Reguliance	hypothyroidism; pituitary thyrotropin suppression	2020/11/30	68:36.04 - Thyroid Agents	5S	214047
Imcivree®	setmelanotide	Rhythm	obesity due to three rare genetic conditions: POMC, PCSK1, LEPR	2020/11/27	28:20.08.92 - Anorexigenic Agents, Miscellaneous	1P/O	213793
Danyelza®	naxitamab-gqgk	Y-Mabs	relapsed or refractory high-risk neuroblastoma in the bone or bone marrow	2020/11/25	10:00 - Antineoplastic Agents		761171
Oxlumo®	lumasiran	Alnylam	primary hyperoxaluria type 1 (PH1)	2020/11/23	92:92 - Other Miscellaneous Therapeutic Agents	1P/O	214103
Zokinvy®	lonafarnib	Eiger	Hutchinson-Gilford progeria syndrome and progeroid laminopathies	2020/11/20	92:92 - Other Miscellaneous Therapeutic Agents	1P/O	213969
	casirivimab; imdevimab	Regeneron	COVID-19	2020/11/20	8:18.24 - Monoclonal Antibodies		EUA
Sutab®	magnesium sulfate; potassium chloride; sodium sulfate	Braintree	colonoscopy preparation	2020/11/10	56:12 - Cathartics and Laxatives	3S	213135
	bamlanivimab	Eli Lilly & Co.	COVID-19	2020/11/10	8:18.24 - Monoclonal Antibodies		EUA

C

Drug Name	Active Ingredients	Company	Indication	Approval Date	AHFS Class	NDA Type	Appl No
Sesquient®	fosphenytoin sodium	Sedor	generalized tonic-clonic status epilepticus	2020/11/05	28:12.12 - Hydantoins	5S	210864
Bronchitol®	mannitol	Chiesi	cystic fibrosis	2020/10/30	48:92 - Respiratory Tract Agents, Misc	10S/O	202049
Eysuvis®	loteprednol etabonate	Kala	short-term treatment of dry eye disease	2020/10/26	52:08.08 - Corticosteroids	5S	210933
Veklury®	remdesivir	Gilead	COVID-19	2020/10/22	8:18.32 - Nucleosides and Nucleotides	1P	214787
Inmaze®	atoltivimab; maftivimab; odesivimab-ebgn	Regeneron	Zaire ebolavirus	2020/10/14	8:18.24 - Monoclonal Antibodies		761169
Alkindi® Sprinkle	hydrocortisone	Diurnal	replacement therapy in pediatric patients with adrenocortical insufficiency	2020/09/29	68:04 - Adrenals	3S	213876
Xeljanz® Oral Solution	tofacitinib citrate	Pfizer	RA, PsA, UC, JIA	2020/09/25	92:36 - Disease-modifying Antirheumatic Drugs	3P	213082
Gavreto®	pralsetinib	Blueprint Medicines	metastatic rearranged during transfection (RET) fusion- positive nonsmall cell lung cancer (NSCLC) with PET for localization of somatostatin receptor positive neuroendocrine tumors (NETs)	2020/09/04	10:00 - Antineoplastic Agents	1P/O	213721
Detectnet®	copper CU-64 dotatate	Radiomedix	metastatic rearranged during transfection (RET) fusion- positive nonsmall cell lung cancer (NSCLC) with PET for localization of somatostatin receptor positive neuroendocrine tumors (NETs)	2020/09/03	36:68 - Roentgenographic and Other Imaging Agents	1P/O	213227
Onureg®	azacitidine	Celgene	acute myeloid leukemia	2020/09/01	10:00 - Antineoplastic Agents	3P/O	214120
Qdolo®	tramadol hydrochloride	Athena	pain	2020/09/01	28:08.08 - Opiate Agonists	3S	214044